# Bioequivalence Study of Individual Atazanavir and Cobicistat Compared With Atazanavir in Fixed-dose Combination With Cobicistat

> **NCT01837719** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 64 (actual)

## Conditions studied

- Human Immunodeficiency Virus Type 1 (HIV-1)

## Interventions

- **DRUG:** Atazanavir
- **DRUG:** Cobicistat
- **DRUG:** Atazanavir/Cobicistat FDC

## Key facts

- **NCT ID:** NCT01837719
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2013-06
- **Final completion:** 2013-06
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2014-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01837719

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01837719, "Bioequivalence Study of Individual Atazanavir and Cobicistat Compared With Atazanavir in Fixed-dose Combination With Cobicistat". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01837719. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*